Our study suggests that TET2 mutational profiling or TET2 protein expression analysis could potentially identify a subgroup of patients with disease that is null for protein expression and acutely sensitive to hypomethylating therapy, suggesting an alternative first-line therapy for frail AML patients or salvage therapy for patients with chemoresistant disease. Here, TET2 is linked to acute myeloid leukemia.